Open Label, Dose Escalation Phase I Study of AZD2281
NCT00572364
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
18
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Malignancies
Interventions
DRUG:
KU-0059436 (AZD2281)(PARP inhibitor)
Sponsor
AstraZeneca